These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 35788562)

  • 21. Inactive disease in patients with lupus is linked to autoantibodies to type I interferons that normalize blood IFNα and B cell subsets.
    Bradford HF; Haljasmägi L; Menon M; McDonnell TCR; Särekannu K; Vanker M; Peterson P; Wincup C; Abida R; Gonzalez RF; Bondet V; Duffy D; Isenberg DA; Kisand K; Mauri C
    Cell Rep Med; 2023 Jan; 4(1):100894. PubMed ID: 36652906
    [TBL] [Abstract][Full Text] [Related]  

  • 22. NFKB2 haploinsufficiency identified via screening for IFN-α2 autoantibodies in children and adolescents hospitalized with SARS-CoV-2-related complications.
    Bodansky A; Vazquez SE; Chou J; Novak T; Al-Musa A; Young C; Newhams M; Kucukak S; Zambrano LD; Mitchell A; Wang CY; Moffitt K; Halasa NB; Loftis LL; Schwartz SP; Walker TC; Mack EH; Fitzgerald JC; Gertz SJ; Rowan CM; Irby K; Sanders RC; Kong M; Schuster JE; Staat MA; Zinter MS; Cvijanovich NZ; Tarquinio KM; Coates BM; Flori HR; Dahmer MK; Crandall H; Cullimore ML; Levy ER; Chatani B; Nofziger R; ; Geha RS; DeRisi J; Campbell AP; Anderson M; Randolph AG
    J Allergy Clin Immunol; 2023 Apr; 151(4):926-930.e2. PubMed ID: 36509151
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The detectable anti-interferon-γ autoantibodies in COVID-19 patients may be associated with disease severity.
    Chen PK; Yeo KJ; Chang SH; Liao TL; Chou CH; Lan JL; Chang CK; Chen DY
    Virol J; 2023 Feb; 20(1):33. PubMed ID: 36810114
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Examination of autoantibodies to type I interferon in patients suffering from long COVID.
    Hansen KS; Jørgensen SE; Skouboe MK; Agergaard J; Schiøttz-Christensen B; Vibholm LK; Tolstrup M; Østergaard L; Leth S; Mogensen TH
    J Med Virol; 2023 Sep; 95(9):e29089. PubMed ID: 37698062
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mild COVID-19 despite autoantibodies against type I IFNs in autoimmune polyendocrine syndrome type 1.
    Meisel C; Akbil B; Meyer T; Lankes E; Corman VM; Staudacher O; Unterwalder N; Kölsch U; Drosten C; Mall MA; Kallinich T; Schnabel D; Goffinet C; von Bernuth H
    J Clin Invest; 2021 Jul; 131(14):. PubMed ID: 34061776
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Alveolar cytokines and interferon autoantibodies in COVID-19 ARDS.
    Jonassen TB; Jørgensen SE; Mitchell NH; Mogensen TH; Berg RMG; Ronit A; Plovsing RR
    Front Immunol; 2024; 15():1353012. PubMed ID: 38571960
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Salivary autoantibodies to type I IFNs: Mirror plasma levels, predispose to severe COVID-19, and enhance feasibility for clinical screening.
    Saheb Sharif-Askari N; Saheb Sharif-Askari F; Bayram OS; Hafezi S; Alsayed HAH; Kasim F; Mdkhana B; Selvakumar B; Alsafar HS; Halwani R
    Heart Lung; 2024; 66():31-36. PubMed ID: 38547583
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The risk of COVID-19 death is much greater and age dependent with type I IFN autoantibodies.
    Manry J; Bastard P; Gervais A; Le Voyer T; Rosain J; Philippot Q; Michailidis E; Hoffmann HH; Eto S; Garcia-Prat M; Bizien L; Parra-Martínez A; Yang R; Haljasmägi L; Migaud M; Särekannu K; Maslovskaja J; de Prost N; Tandjaoui-Lambiotte Y; Luyt CE; Amador-Borrero B; Gaudet A; Poissy J; Morel P; Richard P; Cognasse F; Troya J; Trouillet-Assant S; Belot A; Saker K; Garçon P; Rivière JG; Lagier JC; Gentile S; Rosen LB; Shaw E; Morio T; Tanaka J; Dalmau D; Tharaux PL; Sene D; Stepanian A; Mégarbane B; Triantafyllia V; Fekkar A; Heath JR; Franco JL; Anaya JM; Solé-Violán J; Imberti L; Biondi A; Bonfanti P; Castagnoli R; Delmonte OM; Zhang Y; Snow AL; Holland SM; Biggs CM; Moncada-Vélez M; Arias AA; Lorenzo L; Boucherit S; Anglicheau D; Planas AM; Haerynck F; Duvlis S; Ozcelik T; Keles S; Bousfiha AA; El Bakkouri J; Ramirez-Santana C; Paul S; Pan-Hammarström Q; Hammarström L; Dupont A; Kurolap A; Metz CN; Aiuti A; Casari G; Lampasona V; Ciceri F; Barreiros LA; Dominguez-Garrido E; Vidigal M; Zatz M; van de Beek D; Sahanic S; Tancevski I; Stepanovskyy Y; Boyarchuk O; Nukui Y; Tsumura M; Vidaur L; Tangye SG; Burrel S; Duffy D; Quintana-Murci L; Klocperk A; Kann NY; Shcherbina A; Lau YL; Leung D; Coulongeat M; Marlet J; Koning R; Reyes LF; Chauvineau-Grenier A; Venet F; Monneret G; Nussenzweig MC; Arrestier R; Boudhabhay I; Baris-Feldman H; Hagin D; Wauters J; Meyts I; Dyer AH; Kennelly SP; Bourke NM; Halwani R; Sharif-Askari FS; Dorgham K; Sallette J; Sedkaoui SM; AlKhater S; Rigo-Bonnin R; Morandeira F; Roussel L; Vinh DC; Erikstrup C; Condino-Neto A; Prando C; Bondarenko A; Spaan AN; Gilardin L; Fellay J; Lyonnet S; Bilguvar K; Lifton RP; Mane S; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; Anderson MS; Boisson B; Béziat V; Zhang SY; Andreakos E; Hermine O; Pujol A; Peterson P; Mogensen TH; Rowen L; Mond J; Debette S; de Lamballerie X; Burdet C; Bouadma L; Zins M; Soler-Palacin P; Colobran R; Gorochov G; Solanich X; Susen S; Martinez-Picado J; Raoult D; Vasse M; Gregersen PK; Piemonti L; Rodríguez-Gallego C; Notarangelo LD; Su HC; Kisand K; Okada S; Puel A; Jouanguy E; Rice CM; Tiberghien P; Zhang Q; Casanova JL; Abel L; Cobat A
    Proc Natl Acad Sci U S A; 2022 May; 119(21):e2200413119. PubMed ID: 35576468
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Severe acute herpes virus type 2 primo-infection and its association with anti-type 1 interferon autoantibodies.
    Martinot M; Gravier S; Mohseni-Zadeh M; Fabien N; Casanova JL; Puel A; Goncalves D
    Eur J Clin Microbiol Infect Dis; 2023 Dec; 42(12):1531-1535. PubMed ID: 37870714
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Neutralizing type-I interferon autoantibodies are associated with delayed viral clearance and intensive care unit admission in patients with COVID-19.
    Abers MS; Rosen LB; Delmonte OM; Shaw E; Bastard P; Imberti L; Quaresima V; Biondi A; Bonfanti P; Castagnoli R; Casanova JL; Su HC; Notarangelo LD; Holland SM; Lionakis MS
    Immunol Cell Biol; 2021 Oct; 99(9):917-921. PubMed ID: 34309902
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Type I interferon autoantibodies are associated with systemic immune alterations in patients with COVID-19.
    van der Wijst MGP; Vazquez SE; Hartoularos GC; Bastard P; Grant T; Bueno R; Lee DS; Greenland JR; Sun Y; Perez R; Ogorodnikov A; Ward A; Mann SA; Lynch KL; Yun C; Havlir DV; Chamie G; Marquez C; Greenhouse B; Lionakis MS; Norris PJ; Dumont LJ; Kelly K; Zhang P; Zhang Q; Gervais A; Le Voyer T; Whatley A; Si Y; Byrne A; Combes AJ; Rao AA; Song YS; Fragiadakis GK; Kangelaris K; Calfee CS; Erle DJ; Hendrickson C; Krummel MF; Woodruff PG; Langelier CR; Casanova JL; Derisi JL; Anderson MS; Ye CJ;
    Sci Transl Med; 2021 Sep; 13(612):eabh2624. PubMed ID: 34429372
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Autoantibodies targeting type I interferons: Prevalence, mechanisms of induction, and association with viral disease susceptibility.
    Hale BG
    Eur J Immunol; 2023 Jun; 53(6):e2250164. PubMed ID: 37027328
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Autoantibodies neutralizing type I IFNs are present in
    Bastard P; Gervais A; Le Voyer T; Rosain J; Philippot Q; Manry J; Michailidis E; Hoffmann HH; Eto S; Garcia-Prat M; Bizien L; Parra-Martínez A; Yang R; Haljasmägi L; Migaud M; Särekannu K; Maslovskaja J; de Prost N; Tandjaoui-Lambiotte Y; Luyt CE; Amador-Borrero B; Gaudet A; Poissy J; Morel P; Richard P; Cognasse F; Troya J; Trouillet-Assant S; Belot A; Saker K; Garçon P; Rivière JG; Lagier JC; Gentile S; Rosen LB; Shaw E; Morio T; Tanaka J; Dalmau D; Tharaux PL; Sene D; Stepanian A; Megarbane B; Triantafyllia V; Fekkar A; Heath JR; Franco JL; Anaya JM; Solé-Violán J; Imberti L; Biondi A; Bonfanti P; Castagnoli R; Delmonte OM; Zhang Y; Snow AL; Holland SM; Biggs C; Moncada-Vélez M; Arias AA; Lorenzo L; Boucherit S; Coulibaly B; Anglicheau D; Planas AM; Haerynck F; Duvlis S; Nussbaum RL; Ozcelik T; Keles S; Bousfiha AA; El Bakkouri J; Ramirez-Santana C; Paul S; Pan-Hammarström Q; Hammarström L; Dupont A; Kurolap A; Metz CN; Aiuti A; Casari G; Lampasona V; Ciceri F; Barreiros LA; Dominguez-Garrido E; Vidigal M; Zatz M; van de Beek D; Sahanic S; Tancevski I; Stepanovskyy Y; Boyarchuk O; Nukui Y; Tsumura M; Vidaur L; Tangye SG; Burrel S; Duffy D; Quintana-Murci L; Klocperk A; Kann NY; Shcherbina A; Lau YL; Leung D; Coulongeat M; Marlet J; Koning R; Reyes LF; Chauvineau-Grenier A; Venet F; Monneret G; Nussenzweig MC; Arrestier R; Boudhabhay I; Baris-Feldman H; Hagin D; Wauters J; Meyts I; Dyer AH; Kennelly SP; Bourke NM; Halwani R; Sharif-Askari NS; Dorgham K; Sallette J; Sedkaoui SM; AlKhater S; Rigo-Bonnin R; Morandeira F; Roussel L; Vinh DC; Ostrowski SR; Condino-Neto A; Prando C; Bonradenko A; Spaan AN; Gilardin L; Fellay J; Lyonnet S; Bilguvar K; Lifton RP; Mane S; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; Anderson MS; Boisson B; Béziat V; Zhang SY; Vandreakos E; Hermine O; Pujol A; Peterson P; Mogensen TH; Rowen L; Mond J; Debette S; de Lamballerie X; Duval X; Mentré F; Zins M; Soler-Palacin P; Colobran R; Gorochov G; Solanich X; Susen S; Martinez-Picado J; Raoult D; Vasse M; Gregersen PK; Piemonti L; Rodríguez-Gallego C; Notarangelo LD; Su HC; Kisand K; Okada S; Puel A; Jouanguy E; Rice CM; Tiberghien P; Zhang Q; Cobat A; Abel L; Casanova JL
    Sci Immunol; 2021 Aug; 6(62):. PubMed ID: 34413139
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prevalence of type-1 interferon autoantibodies in adults with non-COVID-19 acute respiratory failure.
    Ghale R; Spottiswoode N; Anderson MS; Mitchell A; Wang G; Calfee CS; DeRisi JL; Langelier CR
    Respir Res; 2022 Dec; 23(1):354. PubMed ID: 36527083
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Kinetics of SARS-CoV-2 Specific and Neutralizing Antibodies over Seven Months after Symptom Onset in COVID-19 Patients.
    Zhu L; Xu X; Zhu B; Guo X; Xu K; Song C; Fu J; Yu H; Kong X; Peng J; Huang H; Zou X; Ding Y; Bao C; Zhu F; Hu Z; Wu M; Shen H
    Microbiol Spectr; 2021 Oct; 9(2):e0059021. PubMed ID: 34550000
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neutralizing Type I Interferon Autoantibodies in Japanese Patients with Severe COVID-19.
    Eto S; Nukui Y; Tsumura M; Nakagama Y; Kashimada K; Mizoguchi Y; Utsumi T; Taniguchi M; Sakura F; Noma K; Yoshida Y; Ohshimo S; Nagashima S; Okamoto K; Endo A; Imai K; Kanegane H; Ohnishi H; Hirata S; Sugiyama E; Shime N; Ito M; Ohge H; Kido Y; Bastard P; Casanova JL; Ohara O; Tanaka J; Morio T; Okada S
    J Clin Immunol; 2022 Oct; 42(7):1360-1370. PubMed ID: 35764767
    [TBL] [Abstract][Full Text] [Related]  

  • 37. High incidence of Epstein-Barr virus, cytomegalovirus, and human-herpes virus-6 reactivations in critically ill patients with COVID-19.
    Simonnet A; Engelmann I; Moreau AS; Garcia B; Six S; El Kalioubie A; Robriquet L; Hober D; Jourdain M
    Infect Dis Now; 2021 May; 51(3):296-299. PubMed ID: 33495765
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Preexisting autoantibodies to type I IFNs underlie critical COVID-19 pneumonia in patients with APS-1.
    Bastard P; Orlova E; Sozaeva L; Lévy R; James A; Schmitt MM; Ochoa S; Kareva M; Rodina Y; Gervais A; Le Voyer T; Rosain J; Philippot Q; Neehus AL; Shaw E; Migaud M; Bizien L; Ekwall O; Berg S; Beccuti G; Ghizzoni L; Thiriez G; Pavot A; Goujard C; Frémond ML; Carter E; Rothenbuhler A; Linglart A; Mignot B; Comte A; Cheikh N; Hermine O; Breivik L; Husebye ES; Humbert S; Rohrlich P; Coaquette A; Vuoto F; Faure K; Mahlaoui N; Kotnik P; Battelino T; Trebušak Podkrajšek K; Kisand K; Ferré EMN; DiMaggio T; Rosen LB; Burbelo PD; McIntyre M; Kann NY; Shcherbina A; Pavlova M; Kolodkina A; Holland SM; Zhang SY; Crow YJ; Notarangelo LD; Su HC; Abel L; Anderson MS; Jouanguy E; Neven B; Puel A; Casanova JL; Lionakis MS
    J Exp Med; 2021 Jul; 218(7):. PubMed ID: 33890986
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Association between anti-interferon-alpha autoantibodies and COVID-19 in systemic lupus erythematosus.
    Gupta S; Nakabo S; Chu J; Hasni S; Kaplan MJ
    medRxiv; 2020 Nov; ():. PubMed ID: 33184616
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CMV seropositivity is a potential novel risk factor for severe COVID-19 in non-geriatric patients.
    Weber S; Kehl V; Erber J; Wagner KI; Jetzlsperger AM; Burrell T; Schober K; Schommers P; Augustin M; Crowell CS; Gerhard M; Winter C; Moosmann A; Spinner CD; Protzer U; Hoffmann D; D'Ippolito E; Busch DH
    PLoS One; 2022; 17(5):e0268530. PubMed ID: 35613127
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.